You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

OCUSULF-30 Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Ocusulf-30, and when can generic versions of Ocusulf-30 launch?

Ocusulf-30 is a drug marketed by Miza Pharms Usa and is included in one NDA.

The generic ingredient in OCUSULF-30 is sulfacetamide sodium. There are three drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the sulfacetamide sodium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Ocusulf-30

A generic version of OCUSULF-30 was approved as sulfacetamide sodium by SANDOZ on October 18th, 1988.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for OCUSULF-30?
  • What are the global sales for OCUSULF-30?
  • What is Average Wholesale Price for OCUSULF-30?
Summary for OCUSULF-30
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 117
Patent Applications: 819
DailyMed Link:OCUSULF-30 at DailyMed
Drug patent expirations by year for OCUSULF-30

US Patents and Regulatory Information for OCUSULF-30

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Miza Pharms Usa OCUSULF-30 sulfacetamide sodium SOLUTION/DROPS;OPHTHALMIC 080660-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

OCUSULF-30 Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Ophthalmic Drugs: A Focus on Emerging Trends and Innovations

Introduction

The ophthalmic drugs market is experiencing a significant surge, driven by various factors including technological advancements, an aging global population, and the increasing prevalence of ocular diseases. This article delves into the market dynamics, financial trajectory, and key innovations shaping the future of ophthalmic drug development.

Global Market Size and Growth

The global ophthalmic drugs market was estimated at USD 33.4 billion in 2022 and is projected to reach USD 61.5 billion by 2032, growing at a CAGR of 6.3% during the forecast period from 2023 to 2032[1][5].

Key Areas of Innovation

Myopia

Myopia, or nearsightedness, is a significant area of focus. While treatments are largely corrective with glasses or contact lenses, innovative drugs aimed at slowing the progression of myopia are in development.

Dry Eye

Dry eye disease is another critical area, with drugs like cyclosporine ophthalmic formulations leading the market. Restasis (cyclosporine), for instance, was the first drug approved for the treatment of moderate-to-severe tear-deficient dry eye and generated $1.29 billion in global sales in 2021[1].

Glaucoma

Glaucoma research is advancing with new compounds and combination therapies. The approval of Rho kinase inhibitors like ripasudil and netarsudil has marked a significant innovation in glaucoma therapy since the 2000s. Combination therapies such as netarsudil/latanoprost are also gaining traction[4].

Age-Related Macular Degeneration (AMD)

AMD is a major focus area, with drugs like Aflibercept and Faricimab (Vabysmo) leading the market. Aflibercept, a fusion protein-based anti-VEGF ophthalmic drug, is the highest-selling anti-VEGF ophthalmic drug globally, with 2022 sales of $9.647 billion. Faricimab, the world's first approved bispecific antibodies ophthalmic drug, has seen rapid sales growth, reaching $1.1 billion in the first six months of 2023[1].

Technological Advancements

Technological advancements in drug delivery systems are enhancing treatment efficacy and patient compliance. For example, Ocular Therapeutix is developing innovative implants such as AXPAXLI, an axitinib intravitreal implant for wet AMD, and PAXTRAVA, a travoprost intracameral implant for glaucoma and ocular hypertension[2].

Market Drivers

Aging Population

The expanding geriatric population globally is a significant driver, as older individuals are more susceptible to chronic eye conditions like AMD, glaucoma, and dry eye disease[3][5].

Chronic Diseases

The global increase in chronic diseases such as diabetes, which are often associated with serious eye complications, also boosts the market growth[3].

Regulatory Approvals

Regulatory approvals for new innovative drugs are rapidly integrating into clinical practice, further supporting market expansion. For instance, the FDA approval of Luxturna, a gene therapy for inherited retinal diseases, marks a significant milestone in ophthalmic drug innovation[1].

Financial Performance and Projections

Revenue Growth

The ophthalmic drugs market is expected to grow significantly, with the prescription drugs segment projected to reach $34.7 billion by 2030 at a CAGR of 5.9%, and the OTC drugs segment growing at a CAGR of 6.8% over the same period[5].

Regional Analysis

The U.S. market is estimated at $10.0 billion in 2023, while China is forecasted to grow at an impressive 10.0% CAGR to reach $12.0 billion by 2030. Other key regions, including Japan, Canada, and Germany, are also showing promising growth trends[5].

Key Players and Innovations

Ocular Therapeutix

Ocular Therapeutix is a notable player, with a market capitalization of $1.41 billion. The company is developing several innovative products, including AXPAXLI and PAXTRAVA, which are in various stages of clinical trials[2].

Aldeyra Therapeutics

Aldeyra's Reproxalap, a first-in-class small molecule RASP inhibitor, is aimed at treating dry eye disease. Although its launch is uncertain due to the need for additional clinical trials, Aldeyra has entered into a commercialization license with AbbVie, which includes significant milestone payments[1].

Consumer Behavior and Preferences

Consumer behavior is shifting towards preferring advanced and more effective treatment options with fewer side effects. This demand is driving ongoing research and development in the ophthalmic drugs market[3].

Challenges and Future Directions

Clinical Trial Success Rates

The success rates of clinical trials for ophthalmic drugs vary, with phase I, II, and III transition success rates at 63%, 26%, and 47%, respectively. This highlights the challenges and uncertainties in drug development[4].

Cost and Accessibility

High-cost treatments, such as Luxturna, which costs about $850,000 for the treatment of both eyes, pose significant challenges in terms of accessibility and affordability[1].

Key Takeaways

  • The global ophthalmic drugs market is projected to grow significantly, driven by technological advancements and an aging population.
  • Innovations in drugs like Aflibercept, Faricimab, and new glaucoma treatments are leading the market.
  • Companies like Ocular Therapeutix and Aldeyra are at the forefront of developing new treatments.
  • Regulatory approvals and consumer demand for effective treatments are key drivers.
  • Challenges include high development costs and variable clinical trial success rates.

FAQs

What is the projected growth rate of the global ophthalmic drugs market?

The global ophthalmic drugs market is projected to grow at a CAGR of 6.3% from 2023 to 2032[1].

Which are the key areas of innovation in ophthalmic drug development?

Key areas include myopia, dry eye disease, glaucoma, and age-related macular degeneration (AMD)[1].

What is the significance of Aflibercept in the ophthalmic drugs market?

Aflibercept is the highest-selling anti-VEGF ophthalmic drug globally, with 2022 sales of $9.647 billion[1].

How are technological advancements impacting the ophthalmic drugs market?

Technological advancements in drug delivery systems are enhancing treatment efficacy and patient compliance, driving market growth[3].

What are the major drivers of the ophthalmic drugs market?

Major drivers include the aging population, increasing prevalence of chronic diseases, and regulatory approvals for new innovative drugs[3][5].

Sources

  1. Biochempeg: Insights into Ophthalmic Drug Innovations and Market Trends.
  2. Simplywall.st: Ocular Therapeutix (Nasdaq:OCUL) - Stock Price, News & Analysis.
  3. Globenewswire: Ophthalmic Pharmaceutical Drugs Business Report 2024.
  4. Frontiers in Medicine: Glaucoma Clinical Research: Trends in Treatment Strategies and Future Directions.
  5. Globenewswire: Ophthalmic Drugs Strategic Business Report 2023-2030.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.